Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Netherlands

Marie Skłodowska-Curie Action · Running

BEAT B-cell Lymphoma BEAT B-cell Lymphoma: Biomarkers of Effective CART19 Assessed in the Tissue Microenvironment

Coordinator
Academisch Ziekenhuis Leiden, Netherlands
Runs
1 May 2024 to 30 April 2027
Status
Running
EU funding
€296k
Total cost
—
Partners
2 organisations in 2 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101148836

What the project is doing

In the project's own words, from its summary on CORDIS.

Project Title: BEAT B-cell Lymphoma: Biomarkers of Effective CART19 Assessed in Tissue microenvironmentB-cell lymphomas, encompassing Follicular Lymphoma (FL) and Large B-cell Lymphoma (LBCL), pose significant health concerns. While the use of T-cells modified with a chimeric antigen receptor targeting CD19 (CART19) offers a potential breakthrough in treating these malignancies, it is imperative to unravel the intricate dynamics between the CART19 and the tumor B-cells within their unique tissue microenvironment (TME).

The ""BEAT B-cell Lymphoma"" initiative is poised to transform lymphoma therapeutic strategies. More than just advancing the status quo, this project is geared towards unveiling novel biomarkers that facilitate immediate feedback on therapeutic outcomes. These newfound markers will empower clinicians and patients with predictive tools for CART19 interventions and serve as cornerstones for redefining inclusion criteria in subsequent clinical trials.

But the ambition of this endeavor goes beyond mere biomarker discovery. It promises in-depth revelations on how CART19 impacts actual patient-derived tissues, deepening our knowledge and inspiring fresh treatment avenues. The short term concrete vision? Fine-tuning CART19's performance and honing the initial patient selection process. As a medical doctor with a specialization in hematopathology, I've offered numerous diagnoses of B-cell lymphomas, grounded in histological and molecular markers predominantly sourced from tumor B-cells.

My foundational training as an immunologist has sharpened my curiosity, drawing my attention to the often underemphasized tissue microenvironment. My affinity for bioinformatics further equips me to navigate and interpret vast datasets efficiently. To ensure the success of this project and to further my journey towards becoming an independent researcher, I partnered with the renowned Alizadeh Lab at Stanford, USA and will later join the de Miranda lab in the Netherlands.""

Topics

Who is involved

OrganisationCityCountryRole
Academisch Ziekenhuis LeidenLeidenNetherlandsCoordinator
Board of Trustees of the Leland Stanford Junior UniversityStanfordUnited StatesAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI